All stock lists
Unlock the score
Braveheart Bio, Inc. (NASDAQ:BRVE)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
21.87+0.43 (+2.01%)
Market cap
$1.55B
Insider Score
Analyst consensus
Listed since
Aug 6, 2026
Website
Insider Score
/ 100
BRVE Insider Score
Braveheart Bio, Inc. has a live Insider Score.
Scored on 10 qualifying trades from 8 insiders in the last 90 days.
BRVE Stock Insider Trading Activity
BRVE stock’s insider trading shows 13 purchases for an estimated $159.03M by company insiders over the last 6 months.
Not enough price history.
Insider Trading Activity (Form 4 Filings)
An insider trade occurs when an individual that has non-public information about a company buys or sells shares of that company’s stock. Examples of insiders include a company’s executive officers (CEO, CFO, COO), its board of directors, and its major shareholders. Insiders are required to submit their trading activity to the SEC through Form 4 filings.
Scored window · last 90 days10 qualifying buys8 insiders$159.03M bought— these are the numbers in the rankings table; the full history below shows every filing (buys, sells and older activity).
| Insider | Action | Shares | Avg Cost | Total | Δ Holdings | Held After | Date | Grade | Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| AH Bio Fund IV, L.P. Other | Buy | 1,100,000 | $18.00 | $19.80M | 12.0% | 10,232,420 | Aug 7, 2026 | — | Form 4 |
| AH Bio Fund IV, L.P. Other | Converted | 9,132,420 | — | — | New | 9,132,420 | Aug 7, 2026 | — | Form 4 |
| Chimovits Erez Director | Buy | 1,666,667 | $18.00 | $30.00M | 16.3% | 11,901,826 | Aug 7, 2026 | BCluster BuyFirst Buy | Form 4 |
| Chimovits Erez Director | Converted | 9,132,420 | — | — | 828% | 10,235,159 | Aug 7, 2026 | — | Form 4 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. Other | Buy | 1,680,000 | $18.00 | $30.24M | 19.8% | 10,185,478 | Aug 7, 2026 | — | Form 4 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. Other | Converted | 9,132,420 | — | — | 1553% | 9,720,546 | Aug 7, 2026 | — | Form 4 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. Other | Converted | 7,990,867 | — | — | 1553% | 8,505,478 | Aug 7, 2026 | — | Form 4 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. Other | Buy | 1,920,000 | $18.00 | $34.56M | 19.8% | 11,640,546 | Aug 7, 2026 | — | Form 4 |
| ORBIMED ADVISORS LLC Director | Buy | 273,333 | $18.00 | $4.92M | New | 273,333 | Aug 7, 2026 | A+Cluster BuyFirst Buy | Form 4 |
| ORBIMED ADVISORS LLC Director | Converted | 9,132,420 | — | — | 828% | 10,235,159 | Aug 7, 2026 | — | Form 4 |
| ORBIMED ADVISORS LLC Director | Buy | 1,666,667 | $18.00 | $30.00M | 16.3% | 11,901,826 | Aug 7, 2026 | BCluster BuyFirst Buy | Form 4 |
| Chimovits Erez Director | Buy | 273,333 | $18.00 | $4.92M | New | 273,333 | Aug 7, 2026 | A+Cluster BuyFirst Buy | Form 4 |
| Rickey James Paul CFO | Buy | 27,777 | $18.00 | $499.99K | 5.6% | 520,927 | Aug 7, 2026 | BCluster BuyFirst Buy | Form 4 |
| Viehbacher Christopher Director | Buy | 83,333 | $18.00 | $1.50M | 15.8% | 609,519 | Aug 7, 2026 | BCluster BuyFirst Buy | Form 4 |
| Malek David I Director | Buy | 4,166 | $18.00 | $74.99K | 0.8% | 533,845 | Aug 7, 2026 | CCluster BuyFirst Buy | Form 4 |
| Anderson Michele A. Other | Buy | 1,111 | $18.00 | $20.00K | 0.3% | 332,161 | Aug 7, 2026 | CCluster BuyFirst Buy | Form 4 |
| Murdoch Travis CEO | Buy | 83,333 | $18.00 | $1.50M | 2.9% | 2,940,670 | Aug 7, 2026 | ACluster BuyFirst Buy | Form 4 |
| Lubner David Charles Director | Buy | 55,555 | $18.00 | $999.99K | New | 55,555 | Aug 7, 2026 | ACluster BuyFirst Buy | Form 4 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. Other | Converted | 7,420,091 | — | — | New | 7,420,091 | Aug 7, 2026 | — | Form 4 |
What these mean— the action is the SEC’s own Form 4 transaction code. Only a buy or a sell is an open-market trade; the rest are transfers, awards and exercises, which is why they carry no price.
- Buy (P) — Open-market or private purchase
- Converted (C) — Conversion of a derivative security into shares
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.